Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer.
Its portfolio also includes Phase IIa for the treatment of pancreatic cancer, as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis, and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction
Cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. It also develops commercial predictive biomarker blood test kit for A3AR.
It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. Incorporated in 1994 and headquartered in Ramat Gan, Israel, the company was formerly known as Can-Fite Technologies Ltd. before rebranding in January 2001.